Malaria Genomes
Curator: Larry H Bernstein, MD, FCAP
Five Malaria Genomes Sequenced
Zimmerman et al.
Whole Genome Sequencing of Field Isolates Provides Robust Characterization of Genetic Diversity in Plasmodium vivax.
Scientists have sequenced the entire genomes of five Plasmodium vivax strains taken from the blood of patients on different continents, providing
- a wealth of new data to help in the future mapping of malarial parasite traits such as
- drug resistance, and
determine how different strains are geographically distributed.
The work, by researchers at Case Western Reserve University and the Cleveland Clinic Lerner Research Institute, has
- identified over 80,000 SNPs that can form the basis of association studies and
- population surveys to study the diversity of P. vivax in a single region.
Malaria. (Photo credit: maestro garabito/escuela potosina)
Malaria distribution map. Most countries with a high distribution of malaria also have a high distribution of parasitic worm infections. (Photo credit: Wikipedia)
English: This thin film Giemsa stained micrograph reveals a mature Plasmodium vivax trophozoite. P. vivax trophozoites show amoeboid cytoplasm, large chromatin dots, and fine, yellowish-brown pigment. RBCs are enlarged 1 1/2 – 2X, and may be distorted. If visible, Schüffner’s dots may appear finer than those seen in P. vivax. (Photo credit: Wikipedia)
Related articles
- New Method For Researching The Anopheles Albimanus Mosquito – Another Spreader Of Human Malaria (medicalnewstoday.com)
- Action Africa Inc. Launches a New Approach Against Malaria in Sierra Leone and Nigeria by Teaching Children to be Proactive Ambassadors (prweb.com)
- Real-Time Loop-Mediated Isothermal Amplification (RealAmp) for the Species-Specific Identification of Plasmodium vivax (plosone.org)
- The Role of Reactive Oxygen Species in Anopheles aquasalis Response to Plasmodium vivax Infection (plosone.org)
- New method for researching understudied malaria-spreading mosquitoes (phys.org)
- New method for researching understudied malaria-spreading mosquitoes (esciencenews.com)
- Cloning the vaccinia virus genome as a bacterial artificial chromosome (pharmaceuticalintelligence.com)
- Tests on Key Malaria Drug Start in Cambodia (cambodiadaily.com)
- Imagine No Malaria Launches “Share the Love” Mother’s Day Campaign (prweb.com)
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.